| Size | Price | Stock | Qty |
|---|---|---|---|
| 250g |
|
||
| Other Sizes |
| Targets |
(2-Aminophenyl)methanol functions as a molecular chaperone that rescues the P123S mutant pendrin. Pendrin is a transmembrane anion exchanger protein encoded by the SLC26A4 gene, and mutations in this gene cause Pendred syndrome, a genetic disorder characterized by sensorineural hearing loss and thyroid goiter. The P123S mutation results in misfolding of the pendrin protein, leading to its retention in the endoplasmic reticulum and loss of function. The compound acts as a chemical chaperone, stabilizing the mutant protein and facilitating its proper folding and trafficking to the plasma membrane. By rescuing the function of the mutant pendrin, the compound may restore anion transport and ameliorate the symptoms of Pendred syndrome. The compound's low dose, long-term effect, and low toxicity make it a promising candidate for the treatment of Pendred syndrome.
|
|---|---|
| ln Vitro |
In vitro, (2-aminophenyl)methanol is used as a molecular chaperone to rescue the P123S mutant pendrin. It is a biochemical reagent that can be used as a biological material or organic compound for life science related research. The compound is used for the study of Pendred syndrome. In medicinal chemistry, it serves as a building block for constructing biologically active molecules. Its amino and alcohol functional groups allow for diverse chemical transformations, including acylation, alkylation, and oxidation. In organic synthesis, it is used as a versatile building block for creating complex molecules efficiently.
|
| ln Vivo |
In vivo, (2-aminophenyl)methanol has the advantages of low dose, long-term effect, and low toxicity, and can be used for the study of Pendred syndrome. The compound's ability to rescue the P123S mutant pendrin suggests that it may have therapeutic potential for the treatment of Pendred syndrome. However, specific in vivo studies on the compound are limited, and comprehensive evaluation in animal models of Pendred syndrome has not been performed. The compound's low toxicity profile makes it a promising candidate for further in vivo evaluation.
|
| Enzyme Assay |
Cell-free assays for (2-aminophenyl)methanol involve studying its ability to rescue the P123S mutant pendrin. The compound is incubated with the mutant pendrin protein in cell-free systems, and protein folding and stability are assessed using biophysical techniques such as circular dichroism spectroscopy, fluorescence spectroscopy, or differential scanning calorimetry. The compound's ability to bind to the mutant protein and stabilize its native conformation can be studied using various analytical techniques. Its chaperone activity can be assessed by measuring the restoration of pendrin function in cell-free assays.
|
| Cell Assay |
Cellular assays for (2-aminophenyl)methanol involve treating cells expressing the P123S mutant pendrin with the compound and assessing pendrin trafficking and function. Cells are treated with the compound at various concentrations, and pendrin localization is assessed by immunofluorescence microscopy. Pendrin function is assessed by measuring anion transport activity. The compound's ability to rescue the mutant pendrin and restore its function is evaluated. These assays are used to study the mechanism of action of the compound and its potential for the treatment of Pendred syndrome.
|
| Animal Protocol |
Animal studies for (2-aminophenyl)methanol are limited. The compound has the advantages of low dose, long-term effect, and low toxicity, and can be used for the study of Pendred syndrome. However, specific in vivo studies on the compound in animal models of Pendred syndrome have not been extensively documented. The compound's low toxicity profile makes it a promising candidate for further in vivo evaluation.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known human metabolites of 2-aminobenzyl alcohol include (2-aminophenyl)methyl hydrogen sulfate. Pharmacokinetic data for (2-aminophenyl)methanol are not well characterized. As a small polar molecule with a molecular weight of 123.15 g/mol, it is expected to have moderate bioavailability if administered. The compound has the advantages of low dose, long-term effect, and low toxicity, suggesting favorable pharmacokinetic properties. However, comprehensive pharmacokinetic studies, including absorption, distribution, metabolism, and excretion, have not been performed. For research purposes, the compound is typically handled as a neat chemical and not administered to living organisms for pharmacokinetic profiling. |
| Toxicity/Toxicokinetics |
Toxicological data for (2-aminophenyl)methanol indicate that it has low toxicity. Standard safety precautions for handling aromatic amines and alcohols apply, including the use of personal protective equipment such as gloves and safety goggles. The compound should be handled in a well-ventilated area, and contact with skin and eyes should be avoided. In case of exposure, affected areas should be rinsed thoroughly with water. The compound is not classified as a carcinogen or mutagen based on available data, but comprehensive toxicological evaluation has not been performed. As with all research chemicals, it should be handled with care and used only in accordance with safety guidelines.
|
| Additional Infomation |
Reports indicate that 2-aminobenzyl alcohol has been found in plants of the genus Justicia gendarussa, and relevant data is available for reference.
(2-Aminophenyl)methanol is a research chemical, not an approved drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is a molecular chaperone that rescues the P123S mutant pendrin. It has the advantages of low dose, long-term effect, and low toxicity, and can be used for the study of Pendred syndrome (a syndromic deafness). The compound is a biochemical reagent that can be used as a biological material or organic compound for life science related research. It is a biochemical reagent that can be used as a biomaterial for life science related research and as a sulfonylation reagent for organic synthesis and drug discovery. It should be stored in a cool, dry place. |
| Molecular Formula |
C7H9NO
|
|---|---|
| Molecular Weight |
123.15
|
| Exact Mass |
123.068
|
| CAS # |
5344-90-1
|
| PubChem CID |
21439
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
275.0±0.0 °C at 760 mmHg
|
| Melting Point |
81-83 °C(lit.)
|
| Flash Point |
126.3±20.4 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.617
|
| LogP |
-0.25
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
9
|
| Complexity |
85
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OCC1=CC=CC=C1N
|
| InChi Key |
VYFOAVADNIHPTR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H9NO/c8-7-4-2-1-3-6(7)5-9/h1-4,9H,5,8H2
|
| Chemical Name |
(2-aminophenyl)methanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.1202 mL | 40.6009 mL | 81.2018 mL | |
| 5 mM | 1.6240 mL | 8.1202 mL | 16.2404 mL | |
| 10 mM | 0.8120 mL | 4.0601 mL | 8.1202 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
